Basic Search  |  Summaries  |  Advanced SearchPenalty: £5,841,286
Year: 2016
Date: 12 February, 2016
Offence Group: competition-related offences
Offence Type: price-fixing or anti-competitive practices
Violation Description: Merck KGaA was fined £5,841,286 in a decision by the CMA that the company accepted money from GlaxoSmithKline to delay entry into the UK market with the generic drug paroxetine (allowing GSKs branded version Seroxat to dominate the market at a higher price), in breach of competition law. Generics (UK) Ltd. was jointly and severally liable for £2,732,765 of the fine. An appeal of the decision is still awaiting final judgment.
Action Type: agency action
Agency: Competition and Markets Authority
Source of Data: (click here)